Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. by Edna O Viegas, Arne Kroidl, Patricia J Munseri, Marco Missanga, Charlotta Nilsson, Nelson Tembe, Asli Bauer, Agricola Joachim, Sarah Joseph, Philipp Mann, Christof Geldmacher, Sue Fleck, Wolfgang Stöhr, Gabriella Scarlatti, Said Aboud, Muhammad Bakari, Leonard Maboko, Michael Hoelscher, Britta Wahren, Merlin L Robb, Jonathan Weber, Sheena McCormack, Gunnel Biberfeld, Ilesh V Jani, Eric Sandström, Eligius Lyamuya, TaMoVac study group

Get full text